Post-cardiac catheterization access site complications and low-molecular-weight heparin following cardiac catheterization

Lee A. MacDonald, Sheridan Meyers, Charles L. Bennett, Dan Fintel, Neal Grosshans, Raffy Syegco, Charles J. Davidson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


The low molecular weight heparin enoxaparin is often administered to patients on long-term anticoagulation regimens who temporarily discontinue warfarin prior to undergoing invasive procedures. The clinical outcome of all enoxaparin-treated patients who underwent cardiac catheterization or coronary artery interventional procedures (n = 119) was evaluated. A total of 5 patients (4.2%) requiring anticoagulation (3 with chronic atrial fibrillation and 2 with ventricular thrombi) developed severe late enoxaparin-associated hemorrhagic or vascular complications at the femoral arterial puncture site between 3 and 11 days postprocedure. Complications included development of femoral arterial pseudoaneurysm (n = 3), hypotension (systolic blood pressure < 90 mmHg) (n = 2), acute decrease in hemoglobin levels to < 8.5 mg/dl (n = 4) and cardiac arrest (n = 1). In patients receiving standard dose enoxaparin after percutaneous invasive cardiac procedures, there is the potential for delayed and severe access site hemorrhagic and vascular complications.

Original languageEnglish (US)
Pages (from-to)60-62
Number of pages3
JournalJournal of Invasive Cardiology
Issue number2
StatePublished - Feb 1 2003


  • Complications
  • Enoxaparin

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Post-cardiac catheterization access site complications and low-molecular-weight heparin following cardiac catheterization'. Together they form a unique fingerprint.

Cite this